Because of contradictory evidence from clinical trials, the association between angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer needs further evaluation. As such, the current study is
NO = number of studies; n = number of patients with adverse events; N = number of patients; RR = risk ratio; 95% CI = 95% confidence interval; NA = not applicable.Overall effect of adverse events in t
